Carone, Giuseppe and Schwierz, Christoph and Xavier, Ana (2012): Cost-containment policies in public pharmaceutical spending in the EU. Published in: European Economy- Economic Papers , Vol. ISSN 1, No. 461 (14. September 2012): pp. 1-64.
This is the latest version of this item.
Download (1MB) | Preview
This paper presents and evaluates pharmaceutical policies in the EU aimed at the rational use of medicines and at keeping pharmaceutical spending under control. Policy makers are growing more aware that by regulating pharmaceutical markets correctly, considerable savings can be achieved without compromising the quality of care. Specifically, the paper makes the case that, by following numerous best-practices in pharmaceutical sector regulations, the value for money of pharmaceutical consumption could be substantially increased. Appropriate regulations can be relevant for pricing, reimbursement, market entry and expenditure control, as well as specific policies targeted at the distribution chain, physicians and patients.
|Item Type:||MPRA Paper|
|Original Title:||Cost-containment policies in public pharmaceutical spending in the EU|
|English Title:||Cost-containment policies in public pharmaceutical spending in the EU|
|Keywords:||rational use of medicines, generic substitution, public pharmaceutical expenditure, pharmaceutical policies, cost-containment, value for money, pharmaceutical sector regulations|
|Subjects:||H - Public Economics > H5 - National Government Expenditures and Related Policies > H51 - Government Expenditures and Health
I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health
I - Health, Education, and Welfare > I0 - General > I00 - General
I - Health, Education, and Welfare > I1 - Health
I - Health, Education, and Welfare > I1 - Health > I10 - General
|Depositing User:||Giuseppe Carone|
|Date Deposited:||21. Oct 2012 05:26|
|Last Modified:||19. Apr 2015 15:47|
Aaserud M., A. T. Dahlgren, J. P. Kosters et al. (2006), 'Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies', Cochrane Database Systematic Review, Vol. (2): CD005979.
Abda (2011), 'German pharmacies: Figures, Data, Facts 2010', downloaded 2nd April 2012 from: http://www.abda.de/fileadmin/assets/ZDF/ZDF_2010/ABDA_ZDF_2010_engl.pdf
Adamski, J., B. Godman, G. Ofierska-Sujkowska et al. (2010), 'Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers', BMC Health Services Research, Vol. 10(153):1-16.
Anton C., P. G. Nightingale, D. Adu et al. (2004), 'Improving prescribing using a rule based prescribing system', Quality and Safety in Health Care, Vol. 13(3):186-190.
Ashworth M., R. Lea, H. Gray et al. (2004), 'How are primary care organizations using financial incentives to influence prescribing?', Journal of Public Health, Vol. 26(1):48-51.
BPI (2011), ' Pharma-Daten 2011', Bundesverband der Pharmazeutischen Indutrie e.V., downloaded 2nd April 2011 from: http://www.bpi.de/fileadmin/media/bpi/ Downloads/Internet/Publikationen/PharmaDaten/Pharmadaten%202011%20DE%20V2.pdf
Chaix-Couturier C., I. Durand-Zaleski, D. Jolly et al. (2000), 'Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues', International Journal of the Quality of Health Care, Vol. 12(2):133-142.
Cutler D., A. Deaton and A. Llerar-Muney (2006), 'The determinants of mortality'. Journal of Economic Perspectives, Vol. 20: 97–120.
Cutler, M. D. and W. Everett (2010), 'Thinking outside the pillbox – medication adherence as a priority for health care reform', The New England Journal of Medicine, pp. 1-3.
Dylst, P., Simoens, S. (2010), 'Generic medicine pricing policies in Europe: current status and impact.', Pharmaceuticals, Vol. 3: 471-481.
Dylst, P., Vulto, A. and S. Simoens (2011a), 'Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?', Health Policy, Vol. 101(2): 146-152.
Dylst, P. and S. Simoens, (2011b) 'Does the market share of generic medicines influence the price level?: A European analysis', PharmacoEconomics, Vol. 29(10):875-882.
EAHC- European Commission (2012), 'EU Pharmaceutical expenditure forecast', Executive Agency for Health and Consumers-EAHC-European Commission (DG SANCO), forthcoming.
EGA (2009), 'How to Increase Patient Access to Generic Medicines in European Healthcare Systems: A Report by the EGA Health Economics Committee' Frank Bongers, Hugo Carradinha, accessed on: http://www.egagenerics.com/doc/ega_increase-patient-access_update_072009.pdf
EGA (2011), '2011 Market Review - The European Generic Medicines Markets', European Generic Medicines Association, Market review.
Espin, J. and J. Rovira (2007), 'Analysis of differences and commonalities in pricing and reimbursement systsems in Europe', commissioned by DG Enterprise and Industry, European Commission: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/ andalusian_school_public_health_report_pricing_2007_en.pdf
Espin, J., J. Rovira and L. Garcia (2011), 'Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines', commissioned by DG Enterprise and Industry, European Commission: http://whocc.goeg.at/Literaturliste/Dokumente/FurtherReading/Experiences%20and%20impact%20of%20European%20risk-sharing%20schemes.pdf
European Commission (DG ECFIN)-EPC (AWG), "The 2012 Ageing Report – Economic and budgetary projections for the 27 EU Member States (2010-2060)", European Economy No. 2/2012.
European Commission (2009), 'Pharmaceutical Sector Inquiry. Final Report', accessed on: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf
European Commission (DG ECFIN)-EPC (AWG), 'Joint Report on Health Systems', European Economy. Occasional Papers, Vol. 74: http://ec.europa.eu/economy_finance/publications/occasional_paper/2010/pdf/ocp74_en.pdf
Eurostat (2007), 'Pharmaceutical products – comparative price levels in 33 European countries in 2005', Statistics in focus, No. 45.
Fraeyman, J., Van Hal, G., De Loof, H. et al. (2011), 'Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium', Poster presented at the PPRI Conference in Vienna: 29 September 2011.
Gill, P.S., M., Makela, K.M., Vermeulen et al. (1999), 'Changing doctor prescribing behaviour'. Pharmacy World & Science, Vol. 21(4):158-167.
Gray, J. (2006), 'Changing physician prescribing behaviour', Canadian Journal of Clinical Pharmacology, Vol. 13(1):81-84.
GÖG (2010), 'Rational use of medicines in Europe', Vienna.
IMS (2010), 'Generic medicines: Essential contributors to the long term health of society. Sector sustainability challenges in Europe', presentation by Alan Sheppard, Brussels, the 25th March 2010.
IMS (2011a), 'Total Unaudited and Audited Global Pharmaceutical Market, 2003 – 2010', Health Market Prognosis, IMS.
IMS (2011b), 'Generic Medicines: Essential contributors to the long-term health of society', accessed on: http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf
Kanavos, P. and J. Costa-Font (2005), 'Pharmaceutical parallel trade in Europe: stakeholder and competition effects', Economic Policy, Vol. 20 (44): 751–798.
Kanavos, P., E. Seeley and S. Vandoros (2009), 'Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium'. DG Enterprise and Industry, European Commission, Brussels, Belgium.
Kanavos, P., W. Schurer and S. Vogler (2011a), 'The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices', Emin€t, Final report, accessed on: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf
Kanavos, P., S. Vandoros, R. Irwin et al. (2011), 'Differences in costs of and access to pharmaceutical products in the EU', DG for Internal Policies, European Parliament, Brussels, Belgium, accessed on: http://www.europarl.europa.eu/document/activities/cont/ 201201/20120130ATT36575/20120130ATT36575EN.pdf
Le Polain, M., M. Franken, M. Koopmanschap and I. Cleemput (2011), 'Les systèmes de remboursement des médicaments: comparaison internationale et recommandations aux décideurs', KCE report, Vol. 147(B): 1-178.
Leopold, C., Habl C. and S. Vogler (2008), 'Tendering of Pharmaceuticals in EU Member States and EEA countries. Results from the country survey.' ÖBIG Forschungs- und Planungs GesmbH, Vienna 2008, accessed on: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/Final_Report_Tendering_June_08.pdf
Leopold, C., S. Vogler, A.K. Mantel-Teeuwisse et al. (2012), 'Differences in external price referencing in Europe - A descriptive Overview', Health Policy, Vol. 104: 50– 60.
Lichtenberg, F. (2010), 'The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France', CESIFO Working Paper No. 3095.
Manning, W. et al. (1988), 'Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment', RAND Corporation, Santa Monica, CA.
McMullin, S.T., T.P. Lonergan, C.S. Rynearson et al. (2004), 'Impact of an evidence-based computerized decision support system on primary care prescription costs', Annals of Family Medicine, Vol. 2(5): 494-498.
OECD (2008), 'Pharmaceutical pricing policies in a global market', OECD Health Policy Studies, accessed on: http://www.oecd.org/document/36/0,3343,en_2649_33929_41000996_ 1_1_1_37407,00.html
PPRI (2008), 'PPRI report', commissioned by European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth, accessed on: http://ppri.oebig.at/ Downloads/Publications/PPRI_Report_final.pdf
Puig-Junoy, J. (2007), 'The impact of generic reference pricing interventions in the statin market', Health Policy, Vol. 84(1): 14-29.
Puig-Junoy, J. (2010), 'Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review', Pharmacoeconomics: Vol. 28(8): 649-663.
Puig-Junoy, J., P. García-Gómez and D. Casado-Marín (2011), 'Free Medicines thanks to Retirement: Moral Hazard and Hospitalization Offsets in an NHS', Tinbergen Institute Discussion Paper, Vol. 108(3): 1-33.
Moreno-Torres, I., J. Puig-Junoy and J. M. Raya (2010), 'The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain' European Journal of Health Economics, Vol. 12: 563-573.
Ringel, J. S., Hosek, S. D., B. A. Vollaard et al. (2005), 'The Elasticity of Demand for Health Care: A Review of the Literature and Its Application to the Military Health System', RAND Health, accessed on: http://www.rand.org/pubs/monograph_reports/2005/MR1355.pdf
Simoens, S. and S. De Coster (2006), 'Potential savings from increased substitution of generic for originator medicines in Europe', Journal of Generic Medicines, Vol. 4: 43-45.
Simoens, S. (2011a), 'Addressing escalating health care costs in ageing populations by increasing generic medicine utilization', Journal of Generic Medicines, Vol. 8(3): 150-156.
Simoens, S. (2011b), 'Health care sustainability and generic substitution', Hospital Pharmacy Europe, Vol. 55: 32-34.
Schulenburg, F. v. d., S. Vandoros and P. Kanavos (2011), 'The effects of d market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors', Health Economics Review, Vol. 1(18): 1-8.
Sood, N., H. d. Vries, I. Gutierrez et al. (2008), 'The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries', Health Affairs, accessed on: http://www.rand.org/pubs/reprints /2009/RAND_RP1381.pdf
Sorenson, C. (2010), ' Use of Comparative Effectiveness Research in Drug Coverage and Pricing Decisions: A Six-Country Comparison', The Commonwealth Fund, July.
Soumerai, S.B., T.J. McLaughlin and J. Avorn (1989), 'Improving drug prescribing in primary care: a critical analysis of the experimental literature', Milbank Quarterly, Vol. 67(2): 268-317.
Usher, C., Tilson, L., Bennett, K. and M. Barry (2011), 'Cost containment interventions introduced on the community drug schemes in Ireland – evaluation of expenditure trends using a national prescription claims database', presentation at the PPRI Conference in Vienna: 29 September 2011.
Vogler, S., Zimmermann, N., Leopold C. et al (2011a), 'Impact of medicines price reductions in Greece and Spain on other European countries applying external price referencing', poster presented at the PPRI Conference in Vienna: 29 September 2011, accessed on: http://whocc.goeg.at/Literaturliste/Dokumente/Posters/DU_Course_Antwerp_EPR_ImpactMedicinesPrices_EL_ES.pdf
Vogler, S. (2011b), 'Pharmaceutical policies in response to the financial crisis – results from policy monitoring in the EU', Southern Medical Review, Vol. 4(2): 22-32.
Vogler, S. (2012), 'The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview.', Generics and Biosimilars Initiative Journal (GaBI Journal), Vol. 1(2): 93-100: http://whocc.goeg.at/Literaturliste/Dokumente/Articles/GJ2%2009j%20Vogler%20European%20focus%20generics.pdf
Vrijens, F., Van de Voorde, C., M.-I. Farfan-Portet et al. (2010), ' Le système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux', KCE report, Vol. 126(B): 1-92.
WIdO (2011), 'Umsatz mit patentgeschützten Arzneimitteln legt weiter zu', Pressemitteilung, accessed on: http://www.wido.de/fileadmin/wido/downloads/pdf_arzneimittel/ wido_arz_pk_avr2011_0911.pdf
Zuidberg, C. (2010), 'The pharmaceutical system of the Netherlands', Vienna, accessed on: http://ppri.oebig.at/Downloads/Publications/The%20pharmaceutical%20system%20of%20the%20Netherlands_FINAL.pdf
Available Versions of this Item
- Cost-containment policies in public pharmaceutical spending in the EU. (deposited 21. Oct 2012 05:26) [Currently Displayed]